Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd: history, ownership, mission, how it works & makes money

From its origins in 1986 in the heparin sodium sector to a publicly listed powerhouse on the Shanghai Stock Exchange (603707.SS), Nanjing King‑Friend Biochemical Pharmaceutical has grown through strategic milestones - formal establishment in Nanjing in 2000, product diversification with enoxaparin, nadroparin and dalteparin in 2004, a Finished Dosage Form plant in 2011, CFDA GMP approval and provincial recognition in 2014, and the Chengdu Jianjin acquisition in 2016 - underpinning an integrated industrial chain that today supports exports to over 60 countries, three FDA‑approved facilities and annual capacity exceeding 200 million syringes and 200 million vials; with 1,360 employees as of December 31, 2024 and a market capitalization above $3 billion, the company generated 3.924 billion yuan in 2024 revenue (formulations: 3.05 billion yuan, non‑heparin formulations up 24.25% to 1.467 billion yuan, while heparin API fell 21.08% and CDMO revenue declined 47.76%), drove net income to 0.826 billion yuan in 2024 (a 536.09% YoY jump aided by release of a 1.244 billion yuan inventory impairment in 2023), derived 76.75% of revenue from foreign markets, supports over 80 US FDA‑approved products, holds more than 60 ANDAs and 10+ CDE approvals, and is positioned by analysts with projected net income of 1.023 billion yuan in 2025 and 1.66 billion yuan by 2027 as it pivots to high‑end formulations and expanded international commercialization (seven formulation products won bids in the tenth national centralized procurement).

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS): Intro

• Founded involvement in heparin sodium: 1986 (origin of core expertise).
• Formal company establishment in Nanjing: 2000 (corporate formation and industry entry).
• Product diversification into LMWH preparations: 2004 (enoxaparin, nadroparin, dalteparin projects launched).
• Finished dosage form (FDF) manufacturing expansion commenced: 2011 (construction of Nanjing FDF plant).
• GMP certification and provincial recognition: 2014 (CFDA GMP pass; Jiangsu Enterprise Technology Center).
• Strategic acquisition: 2016 (Chengdu Jianjin Pharmaceutical acquired to expand product lines).

• Raw-material sourcing and API production: extraction/refinement processes for heparin and LMWH precursors; quality control in centralized labs.
• R&D and formulation: development of LMWH preparations (enoxaparin, nadroparin, dalteparin) and branded generics; clinical/quality studies to support registration.
• FDF manufacturing: sterile and non-sterile dosage form lines housed in GMP-certified facilities (Nanjing FDF plant commissioned post-2011 construction).
• Regulatory and quality assurance: CFDA/NMPA/GMP compliance, provincial technology center validation, batch release testing and pharmacovigilance.
• Sales, distribution and export: domestic hospital and retail channels plus international distribution to multiple markets (company reports supply chains covering dozens of countries/regions).

• API sales: heparin and related intermediate/API sales to other pharmaceutical manufacturers and contract manufacturers.
• Finished dosage sales: LMWH injections and other sterile/non-sterile finished products sold to hospitals, distributors and pharmacies.
• Contract manufacturing and toll processing: fee-based production for third-party developers leveraging GMP FDF capacity.
• Product licensing and partnerships: collaboration revenue from co-development, licensing of formulations and regional distribution agreements.
• M&A-driven product and market expansion: acquiring firms (e.g., Chengdu Jianjin) to add revenue-generating SKUs and customer relationships.

• Specialist in anticoagulant APIs and LMWH finished products with vertical integration from API to FDF.
• Investment in GMP facilities and R&D to move up the value chain from commodity APIs to higher-margin finished medicines.
• Use of M&A to rapidly add product lines and market access (e.g., 2016 Chengdu Jianjin acquisition).
• Regulatory credentials (CFDA GMP) supporting tender participation for hospital procurement and international registrations.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS): History

• Public listing: Shanghai Stock Exchange, ticker 603707.SS.
• Employees: 1,360 (as of December 31, 2024).
• Market capitalization: > $3 billion USD (reflecting sizeable public-market valuation).
• Global certifications: approvals/certifications across China, the United States, the European Union, Japan, and Germany.
• FDA-approved facilities: 3 manufacturing sites.
• Annual sterile capacity: >200 million syringes and >200 million vials.
• Product focus: heparin sodium, low molecular weight heparin (LMWH) and injectable finished dosage forms.
• Strategic partnerships: long-term manufacturing collaborations with several Fortune Global 500 pharmaceutical companies for heparin and LMWH supply.

• Public shareholders: free float on Shanghai Stock Exchange.
• Major shareholders: institutional investors and strategic partners (typical for large-cap Chinese pharmaceutical firms; exact major-holder breakdown available in regulatory filings).
• Corporate governance: standard A-share governance with board and independent directors per SSE rules.

• To supply high-quality anticoagulants and sterile injectables to global pharmaceutical clients and healthcare markets.
• To maintain compliance with international regulatory standards while scaling sterile production and API supply chains.

• Integrated supply chain: production of heparin APIs and conversion into LMWH and finished sterile products in-house, capturing margins across stages.
• Contract manufacturing: long-term supply agreements with global pharma (including Fortune Global 500 firms) provide recurring revenue and volume stability.
• Proprietary and OEM sales: revenue mix from branded products, contract manufacturing, and OEM/CMO services for partners.
• Capacity leverage: large sterile capacity (>200M syringes/vials annually) enables scale-driven cost advantages and contract competitiveness.
• Regulatory differentiation: multi-jurisdictional approvals expand addressable markets (US, EU, Japan, Germany), increasing export sales and price power.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS): Ownership Structure

• Mission and Values: provide high-quality biochemical pharmaceuticals to support critical patient care, with particular emphasis on anticoagulants and injectable biologics.
• Innovation focus: maintain an active R&D pipeline of novel drug candidates and biosimilars to address unmet medical needs.
• Regulatory priority: pursue approvals and compliance with NMPA, US FDA and EMA standards for global market access.
• Vertical integration: control raw-material sourcing through finished product sales to enhance supply-chain stability.
• Sustainability and quality: expand high-end formulations and international footprint while enforcing rigorous quality assurance processes.

• Core products: heparin sodium, low-molecular-weight heparin (LMWH) products, heparin derivatives and related API/intermediate sales.
• Revenue streams: sales of finished dosage forms (injectables), bulk API sales to other manufacturers, contract manufacturing and licensing of biosimilars.
• Competitive moat: end-to-end control of heparin supply chain (raw material extraction/sourcing, purification, synthesis, and formulation) that reduces supply disruption risk and supports margin preservation.

• Major shareholders typically include founding management, strategic corporate investors, and institutional shareholders listed on the Shanghai Stock Exchange; the board emphasizes regulatory and quality oversight consistent with global market ambitions.
• Governance priorities: compliance with global GMP, supply-chain traceability, and international registration/approval roadmaps for key products.

• Pursues NMPA approvals and dossiers aligned to US FDA & EMA expectations; invests in clinical, CMC and quality systems to meet international standards.
• Strategic aim: increase high-end injectable and biosimilar sales share and grow export revenue through strengthened registration and distribution partnerships.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS): Mission and Values

• Integrated supply chain: end-to-end control from API and excipient procurement through aseptic fill-finish, labeling and global logistics to enhance quality assurance and supply reliability.
• Regulatory-accredited manufacturing: facilities accredited by major authorities, including the US FDA, EMA and Japan's PMDA, supporting international market entry and compliance-driven customers.
• Large-scale sterile capacity: systemically scaled production lines for both primary containers and finished injectables to meet global demand peaks and long-term contracts.
• R&D and regulatory focus: in-house formulation, process development and regulatory teams drive clinical-enabling studies, dossier preparation and post-market support.

• Export footprint: products sold to over 60 countries across Asia, Europe, Africa, Latin America and North America.
• US market involvement: manufacturing and supply supporting more than 80 US FDA-approved products and multiple ANDA/ANDA-equivalent filings for sterile generics.
• Certifications: recognized by national regulators in China, the United States, the European Union, Japan and Germany, facilitating multi-jurisdictional approvals and tenders.

• Clinical & regulatory achievements: over 10 Clinical Development Exemptions (CDE) approved drugs and more than 60 ANDAs (or ANDA-equivalent submissions) in the pipeline or approved, reflecting sustained regulatory engagement.
• Product mix: sterile small-molecule injectables, sterile biological excipients and primary packaging (syringes, vials) for hospital and clinic use.

• Syringes: manufacturing capacity exceeding 200 million syringes per year.
• Vials: manufacturing capacity exceeding 200 million vials per year.
• Quality systems: environmental monitoring, batch-release testing and validated aseptic processes aligned to international GMP requirements.

• Contract manufacturing (CMO): long-term supply agreements and capacity reservations for multinational and regional pharma customers.
• Branded & generic supply: sales of finished sterile products to hospitals, wholesalers and national procurement agencies.
• Primary packaging sales: supply of prefilled syringes and vials to other manufacturers and CMOs.
• Regulatory and technical services: dossier support, stability studies and post-approval lifecycle management for partners.

• Public listing: traded on the Shanghai Stock Exchange (603707.SS), with a mix of institutional investors, strategic partners and retail shareholders.
• Corporate governance: board of directors with executive management teams overseeing operations, quality and regulatory affairs; corporate functions include finance, legal, and global sales.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS): How It Works

• Founded as a specialty biochemical and pharmaceutical manufacturer, Nanjing King-Friend is publicly listed on the Shanghai Stock Exchange (603707.SS).
• Ownership is that of a publicly traded enterprise with a mix of institutional investors, retail shareholders and management holdings typical of Chinese mid-cap pharma firms.
• Mission: advance high-value pharmaceutical formulations and global supply of critical biochemical APIs while expanding higher-margin finished products and selective CDMO capabilities.

• R&D and formulation development of high-end finished drugs and specialty preparations (including non-heparin products).
• Production and sale of APIs (notably heparin-related products historically) and finished formulations.
• Selective Contract Development and Manufacturing Organization (CDMO) services for external partners.
• Regulatory, quality control and global distribution channels to serve international markets.

• Primary revenue stream: sale of pharmaceutical products, with strategic emphasis on higher-value formulations rather than commodity APIs.
• Formulations accounted for the bulk of 2024 revenue, reflecting a successful shift toward higher-margin finished products.
• Non-heparin preparations are a major growth engine, showing double-digit growth in 2024.
• Standard heparin API revenue declined sharply, reflecting deliberate de-emphasis and market/price pressures.
• CDMO services exist but produced markedly lower revenue in 2024, signaling need for strategic reassessment or repricing/contract wins.
• Strong international orientation - foreign markets contribute the majority of sales, underscoring global diversification.

• Continue scaling high-end formulations to improve margin mix - formulations were RMB 3.05B of the RMB 3.924B total in 2024.
• Rebalance exposure to commoditized heparin API by further expanding non-heparin finished products and value-added formulations.
• Reassess and reposition CDMO offerings (pricing, capacity utilization, targeted partners) after a 47.76% revenue drop in 2024.
• Leverage international channels where 76.75% of 2024 revenue originated to diversify product and geographic risk.

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd (603707.SS): How It Makes Money

• Core product lines: heparin sodium API, LMWH APIs, and high-end formulations.
• Revenue channels: direct API sales to generic and branded drug makers, finished-dose formulation sales (incl. national centralized procurement), and overseas formulation commercialization/licensing.
• Geographic mix: strong export sales to Europe/North America; growing overseas formulation platform targeting international hospitals and distributors.

• Performance drivers: recovery from 1.244 bn impairment, expanded formulation bids (7 products won in national centralized procurement 10th batch), and export growth.
• Competitive advantages: established global supply chain for heparin APIs, regulatory track record supporting >80 US FDA-approved products, and strategic push into high-value formulations and overseas commercialization.
• Analyst sentiment: majority 'Buy' with forecasts reflecting net income growth to 1.023 bn in 2025 and 1.66 bn by 2027.